Many studies have demonstrated that DHA plays an important role in brain development. Decreased level of plasma DHA is associated with cognitive decline in healthy elderly people and in patients with Alzheimer’s disease.
A randomized, double-blind, placebo-controlled, clinical study was conducted to assess the potential benefits of DHA supplementation on improving cognitive functions in individuals with age-related cognitive decline (ARCD) using the Cambridge Neuropsychological Test Automated Battery, CANTAB
A total of 485 male or female subjects aged ≥55 years with a subjective memory complaint and with Mini-Mental State Examination >26 and a Logical Memory (Wechsler Memory Scale III) baseline score ≥1
standard deviation below younger adults were enrolled.
900 mg/d DHA, provided as (3) soft-gelatin capsules, each containing 300 mg DHA from algal triglyceride oil.
Yurko-Mauro K, McCarthy D, Rom D, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010s; 6(6):456-64
Earlier animal studies have reported that the 2 major omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), might have differential effects on blood pressure BP and heart rate (HR).
This particular study was conducted to assess the differences in the effects of EPA or DHA on ambulatory (BP) and HR in humans.
57 men and women, 21-80 years of age, with fasting HDL levels of ≤ 44 mg/dl (in men) and ≤ 54 mg/dl (in women).
A double-blind, placebo-controlled parallel design trial
4 g/day of DHA, EPA or placebo respectively
DHA is the principal omega-3 fatty acid and is associated with significant reductions in ambulatory blood pressure and heart rate. Thus, these results indicate the important implications of DHA for human nutrition and the food industry.
Maki KC, et al. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr. 2005; 24(3):189-199.
The consumption of long-chain omega-3 polyunsaturated fatty acids (PUFA), including docosahexaenoic acid (DHA) is associated with reduced risk of cardiovascular disease
A double-blind randomized placebo-controlled parallel-design trial was conducted to assess the beneficial effects of algal oil supplement on cardiovascular risk factors.
39 men and 40 women
Subjects were randomized to receive 4 g/day of the algal oil (containing 1.5 g DHA and 0.6 g docosapentaenoic acid (DPA)) or placebo respectively.
DHA/DPA oil supplementation is generally well tolerated and results in significant reductions in the cardiovascular risk factors
Sanders TA, et al. Influence of an algal triacylglycerol containing docosahexaenoic acid (22:6n-3) and docosapentaenoic acid (22:5n-6) on cardiovascular risk factors in healthy men and women. Br J Nutr. 2006; 95(3):525-531.
Randomized, double-blind, controlled clinical trial was conducted to assess the effect of docosahexaenoic acid (DHA) supplementation on fasting lipid responses in men and women with below-average levels of high-density lipoprotein (HDL) cholesterol.
57 men and women, 21-80 years of age, with fasting HDL levels of ≤ 44 mg/dl (in men) and ≤ 54 mg/dl (in women)
Subjects were randomized to receive 1.52 g/day DHA from DHA rich algal triglycerides or olive oil as a control, respectively.
DHA supplementation significantly reduces triglyceride level and triglyceride/HDL cholesterol ratio
Maki KC, et al. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr. 2005;24(3):189-199.
The effectiveness and role of docosahexaenoic acid (DHA) has been proved by numerous clinical studies. The polyunsaturated fatty acids (PUFAs) during pregnancy or early postpartum period have been found to have beneficial effects on duration of gestation . A randomized, double-blind, controlled, clinical trial was conducted to determine the effects of increasing DHA intake during the third trimester of pregnancy on overall pregnancy and birth outcomes. The figure depicts the study design and the observations made.
Smuts CM, Huang M, Mundy D et al. A randomized trial of docosahexaenoic acid supplementation during the third trimester of pregnancy. Obstet Gynecol. 2003;101(3):469-479..